---
title: "Cantor Fitzgerald Remains a Buy on Disc Medicine (IRON)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286261820.md"
description: "Cantor Fitzgerald analyst Kristen Kluska has reiterated a Buy rating on Disc Medicine (IRON) with a price target of $125.00, while the stock closed at $68.53. Kluska, a 5-star analyst, has an average return of 26.7% and a 49.23% success rate. The consensus on Disc Medicine is a Strong Buy with an average price target of $97.67, indicating a potential upside of 42.52%. Stifel Nicolaus also maintains a Buy rating with a $111.00 price target."
datetime: "2026-05-13T12:27:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286261820.md)
  - [en](https://longbridge.com/en/news/286261820.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286261820.md)
---

# Cantor Fitzgerald Remains a Buy on Disc Medicine (IRON)

Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on Disc Medicine yesterday and set a price target of $125.00. The company’s shares closed yesterday at $68.53.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Kluska is a 5-star analyst with an average return of 26.7% and a 49.23% success rate. Kluska covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Capricor Therapeutics, and Soleno Therapeutics.

Currently, the analyst consensus on Disc Medicine is a Strong Buy with an average price target of $97.67, a 42.52% upside from current levels. In a report released on May 11, Stifel Nicolaus also maintained a Buy rating on the stock with a $111.00 price target.

### Related Stocks

- [IRON.US](https://longbridge.com/en/quote/IRON.US.md)
- [DBVT.US](https://longbridge.com/en/quote/DBVT.US.md)
- [CAPR.US](https://longbridge.com/en/quote/CAPR.US.md)
- [SLNO.US](https://longbridge.com/en/quote/SLNO.US.md)
- [SF.US](https://longbridge.com/en/quote/SF.US.md)
- [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md)
- [SFB.US](https://longbridge.com/en/quote/SFB.US.md)
- [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md)
- [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md)

## Related News & Research

- [Stifel Nicolaus Sticks to Their Buy Rating for Disc Medicine (IRON)](https://longbridge.com/en/news/285910632.md)
- [Disc Medicine (IRON) Projected to Post Earnings on Thursday](https://longbridge.com/en/news/284706493.md)
- [Why This Analyst Thinks Texas Instruments Stock Is on the Path to $1 Trillion](https://longbridge.com/en/news/286957345.md)
- [Analyst Reiterates Buy on Dermata, Keeps 12-Month Price Target Unchanged at $4](https://longbridge.com/en/news/286958909.md)
- [LifeSci Capital Sticks to Their Buy Rating for Olema Pharmaceuticals (OLMA)](https://longbridge.com/en/news/286679129.md)